Vaxart
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Vaxart and buy or sell other stocks, ETFs, and their options commission-free!About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV).
CEOSteven Lo
CEOSteven Lo
Employees115
Employees115
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2004
Founded2004
Employees115
Employees115
VXRT Key Statistics
Market cap165.62M
Market cap165.62M
Price-Earnings ratio-3.10
Price-Earnings ratio-3.10
Dividend yield—
Dividend yield—
Average volume2.25M
Average volume2.25M
High today$0.7117
High today$0.7117
Low today$0.66
Low today$0.66
Open price$0.6959
Open price$0.6959
Volume317.01K
Volume317.01K
52 Week high$0.8449
52 Week high$0.8449
52 Week low$0.2606
52 Week low$0.2606
Stock Snapshot
With a market cap of 165.62M, Vaxart(VXRT) trades at $0.69. The stock has a price-to-earnings ratio of -3.10.
On 2026-01-20, Vaxart(VXRT) stock traded between a low of $0.66 and a high of $0.71. Shares are currently priced at $0.69, which is +4.2% above the low and -3.4% below the high.
Vaxart(VXRT) shares are trading with a volume of 317.01K, against a daily average of 2.25M.
In the last year, Vaxart(VXRT) shares hit a 52-week high of $0.84 and a 52-week low of $0.26.
In the last year, Vaxart(VXRT) shares hit a 52-week high of $0.84 and a 52-week low of $0.26.
VXRT News
TipRanks 6d
Vaxart announces publication in npj Vaccines on norovirus candidateVaxart (VXRT) announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose, oral bivalent va...
People also own
Based on the portfolios of people who own VXRT. This list is generated using Robinhood data, and it’s not a recommendation.